IN2014DN08477A - - Google Patents

Info

Publication number
IN2014DN08477A
IN2014DN08477A IN8477DEN2014A IN2014DN08477A IN 2014DN08477 A IN2014DN08477 A IN 2014DN08477A IN 8477DEN2014 A IN8477DEN2014 A IN 8477DEN2014A IN 2014DN08477 A IN2014DN08477 A IN 2014DN08477A
Authority
IN
India
Prior art keywords
treatment
disclosed
methods
cell proliferative
proliferative disorders
Prior art date
Application number
Inventor
Arijit Chakravarty
Jeffrey A Ecsedy
Robert W Kleinfield
Kha N Le
Wen Chyi Shyu
Karthik Venkatakrishnan
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of IN2014DN08477A publication Critical patent/IN2014DN08477A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are methods for the treatment of various cell proliferative disorders. Disclosed in particular are methods for treatment of various cell proliferative disorders by administering a selective inhibitor of Aurora A kinase in combination with taxane based chemotherapy such as paclitaxel or docetaxel.
IN8477DEN2014 2012-03-20 2013-03-19 IN2014DN08477A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261613258P 2012-03-20 2012-03-20
PCT/US2013/032962 WO2013142491A1 (en) 2012-03-20 2013-03-19 Methods of treating cancer using aurora kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2014DN08477A true IN2014DN08477A (en) 2015-05-08

Family

ID=48048255

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8477DEN2014 IN2014DN08477A (en) 2012-03-20 2013-03-19

Country Status (24)

Country Link
US (2) US20130303519A1 (en)
EP (1) EP2827855B1 (en)
JP (1) JP6373252B2 (en)
KR (1) KR102128866B1 (en)
CN (1) CN104271129A (en)
AU (1) AU2013235275B2 (en)
CA (1) CA2868024A1 (en)
EA (1) EA036434B1 (en)
ES (1) ES2746946T3 (en)
GE (2) GEAP201813599A (en)
IL (1) IL234686B (en)
IN (1) IN2014DN08477A (en)
JO (1) JO3630B1 (en)
MA (1) MA37438A1 (en)
MX (1) MX358411B (en)
MY (1) MY175225A (en)
NZ (1) NZ700744A (en)
PH (1) PH12014502109A1 (en)
SG (2) SG11201405621UA (en)
TN (1) TN2014000387A1 (en)
TW (1) TWI649082B (en)
UA (1) UA117455C2 (en)
WO (1) WO2013142491A1 (en)
ZA (1) ZA201407551B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
JP2018502089A (en) * 2014-12-23 2018-01-25 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Combination of RAF inhibitor and AURORA kinase inhibitor
JP6786530B2 (en) * 2015-07-02 2020-11-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Biomarker of response to selective inhibitors of Aurora A kinase
CN114681455A (en) * 2018-08-17 2022-07-01 深圳微芯生物科技股份有限公司 Combination of histone deacetylase inhibitor and protein kinase inhibitor and pharmaceutical application thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
NZ192803A (en) 1979-02-07 1984-08-24 Hoffmann La Roche Pyrimido-2-benzazepines and pharmaceutical compositions
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5747487A (en) 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
TW486480B (en) 1996-03-08 2002-05-11 Zeneca Ltd Azolobenzazepine derivatives and compositions and method of use thereof
WO1998028281A1 (en) 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
RU2198885C2 (en) 1997-09-29 2003-02-20 Мейдзи Сейка Кайся Лтд. Derivatives of tricyclic triazolobenzazepine, methods of their synthesis, pharmaceutical composition and method of treatment of allergic diseases, intermediate compounds and methods of their synthesis
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
WO2000067754A1 (en) 1999-05-12 2000-11-16 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
DK1318997T3 (en) 2000-09-15 2006-09-25 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
SI20848A (en) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Pharmaceutical formulation containing atorvastatin calcium
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (en) 2001-07-20 2003-02-06 Adc Automotive Dist Control Optical sensor device for use in automobile positioned behind transparent panel with lamella elements between latter and optical transmitter-receiver
WO2003013545A1 (en) 2001-08-09 2003-02-20 Actelion Pharmaceuticals Ltd Novel benzo-fused heterocycles as endothelin antagonisits
CN1897950A (en) 2003-10-14 2007-01-17 惠氏公司 Fused aryl and heteroaryl derivatives and methods of use
EP1718303A4 (en) 2004-02-10 2010-09-01 Santarus Inc Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
RS50568B8 (en) 2004-05-14 2019-08-30 Millennium Pharm Inc Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
JP2008520713A (en) 2004-11-17 2008-06-19 ミイカナ セラピューティクス インコーポレイテッド Kinase inhibitor
JP2008526723A (en) 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッド Pyrazole derivatives that modulate the activity of CDK, GSK and Aurora kinase
MX2008008320A (en) 2005-12-23 2008-09-03 Smithkline Beecham Corp Azaindole inhibitors of aurora kinases.
JP2009523784A (en) 2006-01-16 2009-06-25 ジュビラント・オルガノシス・リミテッド Stable pharmaceutical preparation of acid labile compound and method for producing the same
TW200744583A (en) 2006-03-14 2007-12-16 Ranbaxy Lab Ltd Statin stabilizing dosage formulations
DE102006012301A1 (en) 2006-03-15 2007-09-20 Cemag-Anlagenbau-Dessau Gmbh Production of cement clinker
US7718648B2 (en) 2006-08-09 2010-05-18 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
EP2077850A2 (en) 2006-10-31 2009-07-15 Achillion Pharmaceuticals, Inc. Elvucitabine pharmaceutical compositions
CL2007003244A1 (en) 2006-11-16 2008-04-04 Millennium Pharm Inc COMPOUNDS DERIVED FROM PIRIMIDO [5,4-D] [2] BENZAZEPINA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER.
AR065802A1 (en) 2007-03-22 2009-07-01 Schering Corp FORMULATIONS OF TABLETS CONTAINING SALTS OF 8- [(1- (3,5- BIS- (TRIFLUOROMETIL) FENIL) -ETOXI) - METHYL) -8- PHENYL -1, 7- DIAZA- SPIRO [4,5] DECAN - 2- ONA AND TABLETS PREPARED FROM THESE
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
US20110033461A1 (en) * 2008-03-12 2011-02-10 Vladimir Ratushny Combination Therapy for the Treatment of Cancer
US20110212157A1 (en) 2008-06-26 2011-09-01 Anterios, Inc. Dermal delivery
JO3635B1 (en) 2009-05-18 2020-08-27 Millennium Pharm Inc Solid pharmaceutical compositions and processes for their production
JO3434B1 (en) 2009-07-31 2019-10-20 Millennium Pharm Inc Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
CN102770024A (en) 2010-02-19 2012-11-07 米伦纽姆医药公司 4-{[9-Chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepine-2yl]amino}- Crystalline form of sodium 2-methoxybenzoate
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors

Also Published As

Publication number Publication date
GEAP201813599A (en) 2018-06-25
SG10201607741RA (en) 2016-11-29
IL234686B (en) 2020-01-30
JO3630B1 (en) 2020-08-27
HK1206253A1 (en) 2016-01-08
KR20140144215A (en) 2014-12-18
MX358411B (en) 2018-08-20
EP2827855A1 (en) 2015-01-28
US20130303519A1 (en) 2013-11-14
TN2014000387A1 (en) 2015-12-21
MY175225A (en) 2020-06-16
US10213436B2 (en) 2019-02-26
TW201343169A (en) 2013-11-01
ES2746946T3 (en) 2020-03-09
UA117455C2 (en) 2018-08-10
KR102128866B1 (en) 2020-07-01
CN104271129A (en) 2015-01-07
EA036434B1 (en) 2020-11-10
EA201491727A1 (en) 2015-01-30
MA37438A1 (en) 2016-05-31
PH12014502109A1 (en) 2014-12-10
ZA201407551B (en) 2019-01-30
JP2015510945A (en) 2015-04-13
NZ700744A (en) 2016-09-30
SG11201405621UA (en) 2014-10-30
MX2014011324A (en) 2014-12-05
US20160193224A1 (en) 2016-07-07
WO2013142491A1 (en) 2013-09-26
IL234686A0 (en) 2014-11-30
EP2827855B1 (en) 2019-06-26
JP6373252B2 (en) 2018-08-15
GEP20186900B (en) 2018-10-10
AU2013235275A1 (en) 2014-10-23
AU2013235275B2 (en) 2017-12-07
TWI649082B (en) 2019-02-01
CA2868024A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
PH12013501314A1 (en) Anticancer therapy with dual aurora kinase / mek inhibitors
PH12016502066A1 (en) Methods of treating bladder cancer
MX373959B (en) Improved compositions for treating muscular dystrophy
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
MX378934B (en) Methods of treating bladder cancer
MX393818B (en) COMBINATION THERAPIES FOR CANCER TREATMENT.
MX2014012477A (en) Pyrrolopyrazone inhibitors of tankyrase.
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
UY36075A (en) TUBULISINE DERIVATIVES
EA201490559A1 (en) COMPOSITION FOR THE TREATMENT OF Fistula
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
MX2019014986A (en) Methods of treatment of cancer by continuous infusion of coenzyme q10.
WO2013134407A3 (en) Procaspase 3 activation by combination therapy
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MX2016015568A (en) Nucleoside derivatives for the treatment of cancer.
MX2015013021A (en) 5-bromo-indirubins.
IN2014DN08477A (en)
IN2014DN07103A (en)
MX356102B (en) Compounds and methods for treating leukemia.
WO2014188201A3 (en) Medicaments for use in methods of treating cancers which comprise a decreased amount of hk36me
EP2836217A4 (en) Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents
IL235312A0 (en) Taxane compounds, compositions and methods
MX351961B (en) Diazonamide analogs.
MX2015001134A (en) Therapeutic compounds.